Zidovudine therapy and myopathies associated with human immunodeficiency virus infection

Neuromuscular manifestations of HIV/AIDS

The human immunodeficiency virus (HIV) epidemic, now entering its fourth decade, affects approximately 33 million people living in both developed and resource-limited countries. Neurological complications of the peripheral nervous system are common in HIV-infected patients, and neuromuscular pathology is associated with significant morbidity. Peripheral neuropathy is the most common neuromuscular manifestation observed in HIV/AIDS, and in the antiretroviral era, its prevalence has increased. The purpose of this review was to describe the clinical spectrum of neuromuscular disorders in the setting of HIV infection and to provide an approach to diagnosis and management.

Quantitation of blood lymphocyte mitochondrial DNA for the monitoring of antiretroviral drug-induced mitochondrial DNA depletion

OBJECTIVE

To investigate the impact of antiretroviral treatment on the mitochondrial DNA (mtDNA) content of peripheral blood mononuclear cells (PBMCs) from HIV-1-infected patients.

DESIGN

As absolute mtDNA copy numbers widely differ between individuals, we performed a longitudinal analysis where the patient's first historical specimen was obtained as a baseline reference for relative comparison with subsequent samples from that patient.

METHODS

mtDNA and nuclear DNA quantitation per cell (beta-globin gene copies) were both measured by real-time polymerase chain reaction analysis of whole DNA extracts of 361 serial live-cryopreserved PBMCs collected in former trials and clinical follow-ups from 60 individuals with established or recently acquired HIV-1 infections before and during administration of various antiviral combination therapies.

RESULTS

mtDNA amounts were stable or increasing over years of natural HIV-1 infection in untreated patients (n = 7), consistent with our finding of a lack of differences in mtDNA copy numbers in patients with either a long established or recent lentivirus infection. Our quantitation system revealed significant changes in mtDNA copy number depending on the designated triple, quadruple, or quintuple anti-HIV drug combinations. Zidovudine + zalcitabine + ritonavir and zidovudine + lamivudine + didanosine regularly lead to mtDNA depletion in each of the treated patients, whereas none of 7 patients (and 35 cell specimens) receiving a stavudine + lamivudine + indinavir combination had any significant mtDNA content variations. In 7 patients, mtDNA copy numbers returned to pretreatment levels and/or higher levels without any interruption of the previously mtDNA-depleting antiretroviral drug combination.

CONCLUSION

Our assay system allowed the detection of significant changes in the mtDNA content of PBMCs from HIV-1-infected patients taking antiretroviral drugs, as has been reported in the literature with other detection systems. Yet, mtDNA copy numbers regularly diminished during administration of some but not all nucleoside analog-containing combinations. This, plus the occasional finding that depleted mtDNA contents spontaneously increased to baseline levels and/or higher levels during uninterrupted treatment, should raise a note of caution about resorting to the PBMC mtDNA marker for monitoring of antiretroviral drug-related mitochondrial toxicities.

Turns-amplitude analysis assessment of myopathies in HIV-infected patients

Electromyographic interference patterns during a gradual increase in force were studied by means of the turns-amplitude analysis in a series of HIV-infected patients with and without clinical, biological and histological signs of myopathy. Different parameters were evaluated to determine their sensitivity for the diagnosis of the myopathies that occur in this context. The studied parameters were the number of turns (NT), the mean amplitude of the turns (MA) and the ratio NT/MA (RTA). For each parameter, we compared the interest of mean values, calculated at moderate contraction, to that of peak values. In addition, the shape of the cloud of MA plotted versus NT data points was analyzed. The sensitivity of the turns-amplitude analysis was 95% for the diagnosis of myopathy when NT, MA and RTA were taken together into account, versus 80% in the cloud studies. Peak values were the most sensitive criteria, but mean values abnormalities were observed in some cases of zidovudine myopathy, indicating a potential usefulness of this quantitative EMG method in the differential diagnosis among myopathies in HIV-infected patients.